Amphastar Pharmaceuticals Inc. (AMPH) Plunges 4.83% in Four Days, Hits 52-Week Low

Amphastar Pharmaceuticals Inc. (AMPH) shares fell 0.71% today, marking the fourth consecutive day of decline, with a total drop of 4.83% over the past four days. The stock price hit its lowest level since January 2022, with an intraday decline of 1.37%.

The strategy of buying AMPH shares after they reached a recent low and holding for one week resulted in a 31.32% return over the past five years. However, this strategy underperformed the benchmark, which delivered a 56.99% return, resulting in an excess return of -25.66% and a Sharpe ratio of 0.23. The strategy also experienced a maximum drawdown of -56.45% and a volatility of 49.61%, indicating significant risk and losses during periods of market downturns.

Amphastar Pharmaceuticals' stock price has been influenced by several recent developments. The company's financial results for the first quarter of 2025 showed a mixed performance, falling short of analyst expectations. This underperformance contributed to the stock hitting a 52-week low of $22.60. Additionally, the company experienced a slight downturn in revenue, which may raise concerns among potential investors. The stock has decreased by 39.1% recently, making these factors relevant to its current valuation.

On May 12, 2025, JPMorgan downgraded Amphastar Pharmaceuticals from Overweight to Neutral, reducing the price target from $45 to $30. This downgrade signals a decrease in investor confidence in the company's future prospects. The downgrade, combined with the mixed financial results and revenue downturn, has likely contributed to the recent decline in the stock price.